Literature DB >> 19347766

Should natural killer cells be expanded in vivo or ex vivo to maximize their therapeutic potential?

Jeffrey S Miller1.   

Abstract

Mesh：

Substances：

Year:  2009        PMID： 19347766     DOI： 10.1080/14653240902888000

Source DB:  PubMed          Journal:  Cytotherapy        ISSN： 1465-3249            Impact factor:   5.414


× No keyword cloud information.
  6 in total

1.  Highly activated and expanded natural killer cells for multiple myeloma immunotherapy.

Authors:  Tarun K Garg; Susann M Szmania; Junaid A Khan; Antje Hoering; Paul A Malbrough; Amberly Moreno-Bost; Amy D Greenway; Joshuah D Lingo; Xin Li; Shmuel Yaccoby; Larry J Suva; Brian Storrie; Guido Tricot; Dario Campana; John D Shaughnessy; Bijay P Nair; William T Bellamy; Joshua Epstein; Bart Barlogie; Frits van Rhee
Journal:  Haematologica       Date:  2012-03-14       Impact factor: 9.941

2.  Gene expression analysis of ex vivo expanded and freshly isolated NK cells from cancer patients.

Authors:  Kyoung Un Park; Ping Jin; Marianna Sabatino; Ji Feng; Sara Civini; Hanh Khuu; Maria Berg; Richard Childs; David Stroncek
Journal:  J Immunother       Date:  2010 Nov-Dec       Impact factor: 4.456

Review 3.  Monitoring of natural killer cell immunotherapy using noninvasive imaging modalities.

Authors:  Priyanka Jha; Daniel Golovko; Sukhmine Bains; Daniel Hostetter; Reinhard Meier; Michael F Wendland; Heike E Daldrup-Link
Journal:  Cancer Res       Date:  2010-07-14       Impact factor: 12.701

4.  A good manufacturing practice method to ex vivo expand natural killer cells for clinical use.

Authors:  Giovanni F Torelli; Carmela Rozera; Laura Santodonato; Nadia Peragine; Giuseppina D'agostino; Enrica Montefiore; Maria R Napolitano; Domenica M Monque; Davide Carlei; Paola Mariglia; Simona Pauselli; Maria Gozzer; Mahnaz Shafii Bafti; Gabriella Girelli; Anna Guarini; Filippo Belardelli; Robin Foà
Journal:  Blood Transfus       Date:  2015-01-30       Impact factor: 3.443

Review 5.  Exploiting the interplay between innate and adaptive immunity to improve immunotherapeutic strategies for Epstein-Barr-virus-driven disorders.

Authors:  Debora Martorelli; Elena Muraro; Anna Merlo; Riccardo Turrini; Damiana Antonia Faè; Antonio Rosato; Riccardo Dolcetti
Journal:  Clin Dev Immunol       Date:  2012-01-29

6.  Membrane-bound IL-21 promotes sustained ex vivo proliferation of human natural killer cells.

Authors:  Cecele J Denman; Vladimir V Senyukov; Srinivas S Somanchi; Prasad V Phatarpekar; Lisa M Kopp; Jennifer L Johnson; Harjeet Singh; Lenka Hurton; Sourindra N Maiti; M Helen Huls; Richard E Champlin; Laurence J N Cooper; Dean A Lee
Journal:  PLoS One       Date:  2012-01-18       Impact factor: 3.240
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.